CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Epidural Injections for Pain Management

Defines medical necessity, coding, prior authorization expectations, and clinical criteria for epidural steroid injections (cervical, thoracic, lumbar/caudal) for commercial products under BCBSRI.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyEpidural Injections for Pain Management

Policy CodePolicy N/A

Change TypeNo material change

Effective Date09/01/2023

Next Review DateN/A

Key ActionObtain prior authorization via the online tool for commercial products; approved authorizations are valid for up to 4 epidural injections in a 12‑month period.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4max injections per 12 months

90 daysminimum interval

62320-62327, 64479, 64483covered CPT range

Commercialapplies to

Coverage Criteria for Epidural Steroid Injections

Pain severity and classification: Patient has radicular pain classified by Visual Analog Scale (VAS): Category A: >= 7/10 OR Category B: >= 3 and < 7/10.VAS thresholds per category

Source defines Category A and B VAS thresholds.

Distribution and clinical features: Pain is unilateral in a nerve root distribution and, for Category A, is unrelieved by change in body position.

Objective evidence: Nerve root compression demonstrated by imaging or diagnostic testing.

Imaging or testing must demonstrate nerve root compression.

Conservative therapy and response (Category B and other indications): For Category B (VAS 3 to <7) there must be worsening despite conservative treatment as specified below; for other indications continued pain after required conservative therapy is required.

See Conservative therapy criteria block for specific durations.

Contraindications absent: None of the following are present: local infection at the injection site, increased intracranial pressure, or epidural metastases.

Presence of these contraindications would preclude medical necessity.

Conservative therapy criteria

Conservative treatment timing requirements (as stated in policy):

Conservative therapy options for lower severity/worsening criteria: Category B (VAS 3 to <7): trial and worsening despite one or more of the following minimums: NSAIDs or acetaminophen >= 1 week OR physical therapy >= 1 week OR activity modification >= 1 week.variable by severity

Policy lists 1-week minimums for Category B options.

Conservative therapy for persistent pain prior to ESI: Continued pain requires completion of all of the following minimum trials before considering an epidural injection: NSAIDs or acetaminophen >= 3 weeks AND physical therapy >= 6 weeks AND activity modification >= 6 weeks.NSAIDs >=3 weeks; PT >=6 weeks; activity modification >=6 weeks

These durations apply for persistent or nonradicular pain pathways described in policy.

This policy applies to Commercial Products only. For members enrolled in Medicare Advantage plans, refer to the applicable Medicare policy noted in the related policies section; Medicare Advantage coverage determinations are governed by those separate policies and not by this Commercial Products policy.

Epidural steroid injections (ESIs) for nonspecific low back pain are not supported by sufficient high-quality evidence to demonstrate an improvement in net health outcome. Systematic reviews and randomized trials have been inconsistent and most trials were low quality; overall the evidence is insufficient to conclude long-term benefit for nonspecific low back pain.

Required Conservative Management Before Injection

Failure of conservative management per durations listed in policy

Failure of conservative management per durations listed in policy (variable by severity and category):

Short-duration failure (Category B): Minimum trial of one of the following for at least 1 week with continued or worsening pain despite therapy: NSAIDs or acetaminophen >= 1 week OR physical therapy >= 1 week OR activity modification >= 1 week.>= 1 week for listed therapies

Used when Category B criteria apply (VAS 3 to <7) and worsening despite treatment.

Extended-duration failure (persistent pain): Continued pain after completion of all of the following: NSAIDs or acetaminophen >= 3 weeks AND physical therapy >= 6 weeks AND activity modification >= 6 weeks.NSAIDs >=3 weeks; PT >=6 weeks; activity modification >=6 weeks

Required for consideration of ESI in persistent cases per policy.

CPT Codes and Related Coding Details

Covered CPT CodesCPTCovered

62320

Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement; interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance

Covered CPT CodesCPTCovered

62321	Injection(s) , of diagnostic Or therapeutic substance(s) (eg, anesthetic, antispasmodic, steroid, other solution), not including neurolytic substances, including needle Or catheter placement; interlaminar epidural or subarachnoid, cervical Or thoracic; with imaging guidance (e, fluoroscopy Or CT) Opioid
62323	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, steroid, other solution), not including neurolytic substances, including needle Or catheter placement; interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy Or CT) Opioid
62322	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement; interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance
62324	Injection(s) , including indwelling catheter placement; continuous infusion Or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance Opioid
62326	Injection(s) , including indwelling catheter placement; continuous infusion Or intermittent bolus, of diagnostic Or therapeutic substance(s) (eg, anesthetic, antispasmodic, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance opioid

Covered CPT CodesCPTCovered

62325	Injection(s), including indwelling catheter placement; continuous infusion Or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical o thoracic; with imaging guidance (e, fluoroscopy Or CT) Opioid
62327	Injection(s), including indwelling catheter placement; continuous infusion Or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural Or subarachnoid, lumbar r sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)
64479	Injection(s) , anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or thoracic, single level
64483	Injection(s) , anesthetic agent and/or steroid, trans_ foraminal epidural, with imaging guidance (fluoroscopy or CT); lumbar or sacral, single level

inv-08: Visual Analog Scale (VAS) thresholds for categories A and B

VAS — Category AGreater than or equal to 7 out of 10 on the Visual Analog Scale (VAS)

VAS — Category BGreater than or equal to 3 and less than 7 out of 10 on the Visual Analog Scale (VAS)

Use in criteriaCategories A and B are used to classify radicular pain severity for ESI medical necessity

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is recommended for Commercial Products and should be obtained via the online tool for participating providers.

An approved authorization request will be valid for up to 4 epidural injections in a 12‑month period from the requested date of service.
If more than 4 injections are required in the initial 12‑month period, a new authorization request is required.
It is recommended that at least 90 days elapse between epidural injection procedures.

Documentation Required

Required Clinical Documentation

Documentation supporting medical necessity must be provided with the request and retained in the medical record.

Pain severity documented using the Visual Analog Scale (e.g., VAS) with documented score (for example, ≥7/10 for severe and 3–6/10 for moderate radicular pain as specified in criteria).
Description of pain distribution (e.g., unilateral in a nerve root distribution) and whether pain is positional or continuous.
Objective evidence of nerve‑root compression on imaging (MRI/CT) or other diagnostic testing.
Evidence of prior conservative treatments and duration (see conservative therapy requirement below).
Clinical notes that exclude contraindications (local infection at injection site, increased intracranial pressure, epidural metastases).

Step Therapy

Conservative Therapy Requirement

Members must have failed appropriate conservative therapy prior to approval unless urgent clinical indications exist.

For radicular pain with VAS 3–6/10: documented worsening despite conservative treatment (examples below).
For radicular pain with VAS ≥7/10: conservative measures as clinically appropriate per criteria, and documentation of severity and distribution.
Examples of conservative therapy and minimum durations:
- NSAIDs or acetaminophen for ≥3 weeks (or for ≥1 week in some scenarios where noted),
- Physical therapy for ≥6 weeks (or ≥1 week when specified for initial classification),
- Activity modification for ≥6 weeks (or ≥1 week when specified for initial classification).
Specify exact treatments tried (medication names/doses, physical therapy type/frequency, dates) and patient response.

Denial Risk

Frequency Limit Exceedance — Denial Risk

Exceeding the frequency limits may lead to denial of service if criteria are not met.

Requests for more than 4 epidural injections in any 12‑month period will require a new authorization and are subject to review.
Inter‑injection intervals shorter than the recommended 90 days may be denied unless clinically justified and documented in the record.

Limits on Number and Timing of Epidural Injections

inv-18: epidural injections — maximum of 4 injections in a 12-month period

Maximum injections per 12 monthsAn approved authorization is valid for up to 4 epidural injections in one 12-month period

Authorization requirementAn additional authorization is required if member is to exceed the initially approved number of injections

Applies toCommercial Products (prior authorization via online tool)

inv-19: epidural injections — minimum interval of 90 days between injections

Minimum intervalIt is recommended that a period of no less than 90 days occur between injections

Frequency implicationsInjections administered with less than a 90-day interval may require additional authorization or be subject to denial

ContextRecommendation applies when medical criteria in this policy are met for Commercial Products

Imaging and Procedural Approach Requirements

Billing Rule

Use and document imaging guidance for listed epidural CPT codes

Fluoroscopic or CT guidance is recommended/used for multiple epidural CPT codes; imaging guidance is described for the listed transforaminal and interlaminar procedure codes.

CPT codes with imaging guidance: 62321, 62323, 62325, 62327, 64479, 64483
Fluoroscopic or CT guidance is commonly used and may improve needle placement accuracy

Background and Scope

Epidural steroid injections (ESIs) are local injections of steroid (often with anesthetic) into the epidural space intended to reduce inflammation and relieve pressure on nerve roots or other pain-generating structures. They are used as an option for patients with radicular symptoms or back/neck pain who have not responded to conservative therapies. Trials and meta-analyses report mixed short- and intermediate-term benefits for some indications; long-term benefit is generally not demonstrated and serious adverse events, while uncommon, have been reported.

Key Definitions

inv-15: Epidural steroid injection (ESI) — definition and shorthand

TermEpidural steroid injection (ESI)

Procedure descriptionInjection performed by inserting a needle into the epidural space (between the dura and ligamentum flavum) and injecting a steroid preparation

ApproachesMultiple approaches may be used including translaminar, transforaminal, and caudal

Fluoroscopic useMay be administered with or without fluoroscopic guidance; fluoroscopy commonly used to improve needle placement accuracy

inv-16: Radiculopathy — definition: back pain with radicular distribution, numbness, or weakness

DefinitionRadiculopathy: back pain associated with irritation of one or more spinal nerve roots

Common symptomsRadiating pain in a dermatomal distribution, numbness, muscle weakness, or loss of reflexes

Typical courseMost patients respond to conservative care with symptom resolution within weeks to months; a subset may have persistent or progressive deficits prompting further intervention

Not Covered / Experimental Use

Epidural injections for nonspecific low back pain are listed as not covered when the intent is to treat mechanical or nonspecific low back pain without demonstrated nerve-root pathology, because the evidence is insufficient to show meaningful clinical benefit. Use of ESIs for nonspecific low back pain should be evaluated against the policy’s medical necessity criteria and the available trial evidence, which does not reliably show improvement in key outcomes.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyEpidural Injections for Pain Management

Policy CodePolicy N/A

Change TypeNo material change

Effective Date09/01/2023

Next Review DateN/A

Key ActionObtain prior authorization via the online tool for commercial products; approved authorizations are valid for up to 4 epidural injections in a 12‑month period.

SourceLink

On This Page